Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.59 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 9/20 | 0.48 |
| ▸ | CDK1 | P06493 | 9/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 5/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185394 | 0.81 | FLT3 (0.50) | FLT3MKNK1MKNK2EIF2AK2CCNB2 | |
| SCHEMBL3638026 | 0.81 | FLT3 (0.55) | FLT3MKNK1MKNK2EIF2AK2CCNB2 | |
| SCHEMBL8446973 | 0.78 | ZAP70 (0.55) | FLT3MKNK1MKNK2EGFRPRKCA | |
| SCHEMBL31588329 | 0.76 | CCNB2 (0.76) | FLT3MKNK1MKNK2EIF2AK2CCNB2 | |
| SCHEMBL144954 | 0.76 | CCNB2 (0.76) | FLT3MKNK1MKNK2EIF2AK2CCNB2 | |
| SCHEMBL22725596 | 0.73 | CCR4 (0.63) | — | |
| SCHEMBL1593016 | 0.73 | PRKCD (0.79) | CCNB2CDK1CCNB1CCNB3ABL1 | |
| SCHEMBL4765871 | 0.73 | IKBKB (0.55) | ABL1EGFRPRKCAPRKCDMAPK8 | |
| SCHEMBL22725711 | 0.72 | ROCK1 (0.45) | FLT3MKNK1MKNK2CDK1EGFR | |
| SCHEMBL6654114 | 0.72 | ATM (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020243519-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | FLT3 2575/4885MKNK1 2243/4885MKNK2 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.